Cited by 1,558SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections StudiesCOVID-19 Clinical Research Studies

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Spike mutation D614G alters SARS-CoV-2 fitness

Open access

Plante, Jessica A., Liu, Yang, Liu, Jianying, Xia, Hongjie, Johnson, Bryan A., Lokugamage, Kumari G., Zhang, Xianwen, Muruato, Antonio E., Zou, Jing, Fontes-Garfias, Camila R., Mirchandani, Divya, Scharton, Dionna, Bilello, John P., Ku, Zhiqiang, An, Zhiqiang, Kalveram, Birte, Freiberg, Alexander N., Menachery, Vineet D., Xie, Xuping, Plante, Kenneth S., Weaver, Scott C., Shi, Pei-Yong·2021·Nature

DOI 10.1038/s41586-020-2895-3PMC PMC8158177

Published version of a preprint

Open this paper in CoChat — free account Open PDF

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein substitution D614G became dominant during the coronavirus disease 2019 (COVID-19) pandemic 1,2. However, the effect of this variant on viral spread and vaccine efficacy remains to be defined. Here we engineered the spike D614G substitution in the USA-WA1/2020 SARS-CoV-2 strain, and found that it enhances viral replication in human lung epithelial cells and primary human airway tissues by increasing the infectivity and stability of virions. Hamsters infected with SARS-CoV-2 expressing spike(D614G) (G614 virus) produced higher infectious titres in nasal washes and the trachea, but not in the lungs, supporting clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission. Sera from hamsters infected with D614 virus exhibit modestly higher neutralization titres against G614 virus than against D614 virus, suggesting that the mutation is unlikely to reduce the ability of vaccines in clinical trials to protect against COVID-19, and that therapeutic antibodies should be tested against the circulating G614 virus. Together with clinical findings, our work underscores the importance of this variant in viral spread and its implications for vaccine efficacy and antibody therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/s41586-020-2895-3

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
Virological assessment of hospitalized patients with COVID-2019
Wölfel, R., Corman, V. M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M. A., Niemeyer, D., Jones, T. C., Vollmar, P., Rothe, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2196-x · Cited by 6,661
Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus
Korber, B., Fischer, W. M., Gnanakaran, S., Yoon, H., Theiler, J., Abfalterer, W., Hengartner, N., Giorgi, E. E., Bhattacharya, T., Foley, B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.043 · Cited by 4,281
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237
The New Statistics: Why and How
Cumming, G. (2014) · Psychological Science · doi:10.1177/0956797613504966 · Cited by 3,200
SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes
HCA Lung Biological Network, Sungnak, W., Huang, N., Bécavin, C., Berg, M., Queen, R., Litvinukova, M., Talavera-López, C., Maatz, H., Reichart, D., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0868-6 · Cited by 2,501
A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells
Hoffmann, M., Kleine-Weber, H., & Pöhlmann, S. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.04.022 · Cited by 1,852
Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report
Mulligan, M. J., Lyke, K. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Raabe, V., Bailey, R., Swanson, K. A., et al. (2020) · doi:10.1101/2020.06.30.20142570 · Cited by 1,569
Self-citation
SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract
Hou, Y. J., Okuda, K., Edwards, C. E., Martinez, D. R., Asakura, T., Dinnon, K. H., Kato, T., Lee, R. E., Yount, B. L., Mascenik, T. M., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.042 · Cited by 1,488

Show all 37 references

Research works printed but not linked: 1

Mulligan, M. J. et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature 586, 589–593 (2020). · DOI · Paper page

Sorted by citations

Items 101–200 of 1,008

Molecular dynamic simulation reveals E484K mutation enhances spike RBD-ACE2 affinity and the combination of E484K, K417N and N501Y mutations (501Y.V2 variant) induces conformational change greater than N501Y mutant alone, potentially resulting in an escape mutantPreprint
Nelson, G., Buzko, O. V., Spilman, P., Niazi, K. R., Rabizadeh, S., & Soon‐Shiong, P. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.13.426558 · Cited by 180
SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera
Kuzmina, A., Khalaila, Y., Voloshin, O., Keren‐Naus, A., Cohen, L. B., Raviv, Y., Shemer‐Avni, Y., Rosenberg, E., & Taube, R. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.03.008 · Cited by 177
Mutations in SARS-CoV-2 variants of concern link to increased spike cleavage and virus transmission
Escalera, A., Gonzalez-Reiche, A. S., Aslam, S., Mena, I., Laporte, M., Pearl, R. L., Fossati, A., Rathnasinghe, R., Alshammary, H., van de Guchte, A., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.01.006 · Cited by 173
Defining the risk of SARS-CoV-2 variants on immune protection
DeGrace, M. M., Ghedin, E., Frieman, M. B., Krammer, F., Grifoni, A., Alisoltani, A., Alter, G., Amara, R. R., Baric, R. S., Barouch, D. H., et al. (2022) · Nature · doi:10.1038/s41586-022-04690-5 · Cited by 168
Self-citation
V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity
Ou, J., Zhou, Z., Dai, R., Zhang, J., Zhao, S., Wu, X., Lan, W., Ren, Y., Cui, L., Lan, Q., et al. (2021) · Journal of Virology · doi:10.1128/jvi.00617-21 · Cited by 169
Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice
Scheaffer, S. M., Lee, D., Whitener, B., Ying, B., Wu, K., Liang, C.-Y., Jani, H., Martin, P., Amato, N. J., Avena, L. E., et al. (2023) · Nature Medicine · doi:10.1038/s41591-022-02092-8 · Cited by 169
Nucleocapsid mutations in SARS-CoV-2 augment replication and pathogenesis
Johnson, B. A., Zhou, Y., Lokugamage, K. G., Vu, M. N., Bopp, N. E., Crocquet-Valdes, P. A., Kalveram, B., Schindewolf, C., Liu, Y., Scharton, D., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010627 · Cited by 161
Self-citation
A versatile reverse genetics platform for SARS-CoV-2 and other positive-strand RNA viruses
Amarilla, A. A., Sng, J. D. J., Parry, R. H., Deerain, J. M., Potter, J. R., Setoh, Y. X., Rawle, D. J., Le, T. T., Modhiran, N., Wang, X., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23779-5 · Cited by 159
The N501Y spike substitution enhances SARS-CoV-2 transmission
Liu, Y., Liu, J., Plante, K. S., Plante, J. A., Xie, X., Zhang, X., Ku, Z., An, Z., Scharton, D., Schindewolf, C., et al. (2021) · doi:10.1101/2021.03.08.434499 · Cited by 574
Self-citation
SARS-CoV-2 one year on: evidence for ongoing viral adaptation
Peacock, T. P., Penrice-Randal, R., Hiscox, J. A., & Barclay, W. (2021) · Journal of General Virology · doi:10.1099/jgv.0.001584 · Cited by 155
Emergence of a Highly Fit SARS-CoV-2 Variant
Baric, R. S. (2020) · New England Journal of Medicine · doi:10.1056/nejmcibr2032888 · Cited by 153
Neutralising antibody escape of SARS‐CoV‐2 spike protein: Risk assessment for antibody‐based Covid‐19 therapeutics and vaccines
Focosi, D., & Maggi, F. (2021) · Reviews in Medical Virology · doi:10.1002/rmv.2231 · Cited by 150
Interferon resistance of emerging SARS-CoV-2 variants
Guo, K., Barrett, B. S., Morrison, J. H., Mickens, K. L., Vladar, E. K., Hasenkrug, K. J., Poeschla, E. M., & Santiago, M. L. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2203760119 · Cited by 141
Molecular Architecture of Early Dissemination and Massive Second Wave of the SARS-CoV-2 Virus in a Major Metropolitan Area
Long, S. W., Olsen, R. J., Christensen, P. A., Bernard, D. W., Davis, J. J., Shukla, M. P., Nguyen, M., Saavedra, M. O., Yerramilli, P., Pruitt, L., et al. (2020) · mBio · doi:10.1128/mbio.02707-20 · Cited by 145
Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice
Pymm, P., Adair, A., Chan, L., Cooney, J. P., Mordant, F. L., Allison, C. C., López, E., Haycroft, E. R., O’Neill, M. T., Tan, L. L., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2101918118 · Cited by 137
Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2
Evans, J. P., Zeng, C., Qu, P., Faraone, J. N., Zheng, Y.-M., Carlin, C., Bednash, J. S., Zhou, T., Lozanski, G., Mallampalli, R. K., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.04.014 · Cited by 134
Evolutionary trajectory of SARS-CoV-2 and emerging variants
Singh, J., Pandit, P., McArthur, A. G., Banerjee, A., & Mossman, K. L. (2021) · Virology Journal · doi:10.1186/s12985-021-01633-w · Cited by 150
Cytokine storm in COVID-19: from viral infection to immune responses, diagnosis and therapy
Jiang, Y.-Z., Rubin, L., Peng, T., Liu, L., Xing, X., Lazarovici, P., & Zheng, W. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59272 · Cited by 144
Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants
Sun, C., Xie, C., Bu, G., Zhong, L., & Zeng, M. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01039-2 · Cited by 149
N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2
McCallum, M., Marco, A. D., Lempp, F., Tortorici, M. A., Pinto, D., Walls, A. C., Beltramello, M., Chen, A., Liu, Z., Zatta, F., et al. (2021) · doi:10.1101/2021.01.14.426475 · Cited by 901
Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression of ACE2 and TMPRSS2
Neerukonda, S. N., Vassell, R. A., Herrup, R., Liu, S., Wang, T. T., Takeda, K., Yang, Y., Lin, T.-L., Wang, W., & Weiss, C. D. (2021) · PLoS ONE · doi:10.1371/journal.pone.0248348 · Cited by 133
Two Years into the COVID-19 Pandemic: Lessons Learned
da Silva, S. J. R., do Nascimento, J. C. F., Mendes, R. P. G., Guarines, K. M., da Silva, C. T. A., da Silva, P. G., de Magalhães, J. J. F., Vigar, J. R. J., Silva‐Júnior, A., Kohl, A., et al. (2022) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.2c00204 · Cited by 155
A Comparative Analysis of SARS-CoV-2 Antivirals Characterizes 3CL pro Inhibitor PF-00835231 as a Potential New Treatment for COVID-19
de Vries, M., Mohamed, A., Prescott, R. A., Valero-Jimenez, A. M., Desvignes, L., O’Connor, R., Steppan, C. M., Devlin, J. C., Ivanova, E. N., Herrera, A. M., et al. (2021) · Journal of Virology · doi:10.1128/jvi.01819-20 · Cited by 137
mRNA vaccination of naive and COVID-19-recovered individuals elicits potent memory B cells that recognize SARS-CoV-2 variants
Sokal, A., Spaeth, G. B., Fernández, I., Broketa, M., Azzaoui, I., Selle, A. D. L., Vandenberghe, A., Fourati, S., Roeser, A., Meola, A., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.09.011 · Cited by 135
The D614G mutations in the SARS-CoV-2 spike protein: Implications for viral infectivity, disease severity and vaccine design
Groves, D. C., Rowland‐Jones, S., & Angyal, A. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.10.109 · Cited by 131
Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination
Gorman, M. J., Patel, N., Guebre‐Xabier, M., Zhu, A. L., Atyeo, C. G., Pullen, K. M., Loos, C., Goez-Gazi, Y., Carrion, R., Tian, J.-H., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100405 · Cited by 121
The SARS-CoV-2 and other human coronavirus spike proteins are fine-tuned towards temperature and proteases of the human airways
Laporte, M., Raeymaekers, V., Berwaer, R. V., Vandeput, J., Marchand-Casas, I., Thibaut, H. J., Looveren, D. V., Martens, K., Hoffmann, M., Maes, P., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009500 · Cited by 126
Protein N-myristoylation: functions and mechanisms in control of innate immunity
Wang, B., Dai, T., Sun, W., Wei, Y., Ren, J., Zhang, L., Zhang, M., & Zhou, F. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00663-2 · Cited by 128
The emerging SARS-CoV-2 variants of concern
Sanyaolu, A. O., Okorie, C., Marinkovic, A., Haider, N., Abbasi, A. F., Jaferi, U., Prakash, S., & Balendra, V. (2021) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361211024372 · Cited by 122
Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models
Hajnik, R. L., Plante, J. A., Liang, Y., Alameh, M.-G., Tang, J., Bonam, S. R., Zhong, C., Adam, A., Scharton, D., Rafael, G. H., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abq1945 · Cited by 122
Self-citation
Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum
Bates, T. A., Leier, H. C., Lyski, Z. L., McBride, S. K., Coulter, F. J., Weinstein, J. B., Goodman, J. R., Lu, Z., Siegel, S. A. R., Sullivan, P. D., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25479-6 · Cited by 115
Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection
Zou, J., Xia, H., Xie, X., Kurhade, C., Machado, R. R. G., Weaver, S. C., Ren, P., & Shi, P. (2022) · Nature Communications · doi:10.1038/s41467-022-28544-w · Cited by 114
Self-citation
SARS-CoV-2 spike engagement of ACE2 primes S2′ site cleavage and fusion initiation
Yu, S., Zheng, X., Zhou, B., Li, J., Chen, M., Deng, R. X., Wong, G., Lavillette, D., & Meng, G. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2111199119 · Cited by 130
Structure-Function Analyses of New SARS-CoV-2 Variants B.1.1.7, B.1.351 and B.1.1.28.1: Clinical, Diagnostic, Therapeutic and Public Health Implications
Singh, J., Samal, J., Kumar, V., Sharma, J., Agrawal, U., Ehtesham, N. Z., Sundar, D., Rahman, S. A., Hira, S., & Hasnain, S. E. (2021) · Viruses · doi:10.3390/v13030439 · Cited by 118
Animal Models for COVID-19: Hamsters, Mouse, Ferret, Mink, Tree Shrew, and Non-human Primates
Shou, S., Liu, M., Yang, Y., Kang, N., Song, Y., Tan, D., Liu, N., Wang, F., Liu, J., & Xie, Y. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.626553 · Cited by 120
Self-citation
Present variants of concern and variants of interest of severe acute respiratory syndrome coronavirus 2: Their significant mutations in S‐glycoprotein, infectivity, re‐infectivity, immune escape and vaccines activity
Chakraborty, C., Bhattacharya, M., & Sharma, A. R. (2022) · Reviews in Medical Virology · doi:10.1002/rmv.2270 · Cited by 111
The Spike of Concern—The Novel Variants of SARS-CoV-2
Winger, A., & Caspari, T. (2021) · Viruses · doi:10.3390/v13061002 · Cited by 122
The roles of APOBEC-mediated RNA editing in SARS-CoV-2 mutations, replication and fitness
Kim, K., Calabrese, P., Wang, S., Qin, C., Rao, Y., Feng, P., & Chen, X. S. (2022) · Scientific Reports · doi:10.1038/s41598-022-19067-x · Cited by 115
SARS-CoV-2 Omicron variant causes mild pathology in the upper and lower respiratory tract of hamsters
Armando, F., Beythien, G., Kaiser, F. K., Allnoch, L., Heydemann, L., Rosiak, M., Becker, S., González-Hernández, M., Lamers, M. M., Haagmans, B. L., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31200-y · Cited by 118
Developing RT-LAMP assays for rapid diagnosis of SARS-CoV-2 in saliva
Huang, X., Tang, G., Ismail, N., & Wang, X. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103736 · Cited by 110
Replication kinetics and infectivity of SARS-CoV-2 variants of concern in common cell culture models
Mautner, L., Hoyos, M., Dangel, A., Berger, C., Ehrhardt, A., & Baiker, A. E. (2022) · Virology Journal · doi:10.1186/s12985-022-01802-5 · Cited by 107
The Emergence of SARS-CoV-2 Variants of Concern Is Driven by Acceleration of the Substitution Rate
Tay, J. H., Porter, A. F., Wirth, W., & Duchêne, S. (2022) · Molecular Biology and Evolution · doi:10.1093/molbev/msac013 · Cited by 106
SARS-CoV-2 variants evolve convergent strategies to remodel the host response
Bouhaddou, M., Reuschl, A., Polacco, B. J., Thorne, L., Ummadi, M. R., Ye, C., Rosales, R., Pelin, A., Batra, J., Jang, G. Μ., et al. (2023) · Cell · doi:10.1016/j.cell.2023.08.026 · Cited by 120
Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals
Chen, E. C., Gilchuk, P., Zost, S. J., Suryadevara, N., Winkler, E. S., Cabel, C. R., Binshtein, E., Chen, R. E., Sutton, R. E., Rodriguez, J. L., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109604 · Cited by 102
From Alpha to Omicron: How Different Variants of Concern of the SARS-Coronavirus-2 Impacted the World
Andre, M., Lau, L. S., Pokharel, M. D., Ramelow, J., Owens, F., Souchak, J., Akkaoui, J., Ales, E., Brown, H. H., Shil, R. K., et al. (2023) · Biology · doi:10.3390/biology12091267 · Cited by 122
HIV-1 and SARS-CoV-2: Patterns in the evolution of two pandemic pathogens
Fischer, W., Giorgi, E. E., Chakraborty, S., Nguyen, K., Tanmoy Bhattacharya, A., Theiler, J. P., Goloboff, P. A., Yoon, H., Abfalterer, W., Foley, B. T., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.05.012 · Cited by 109
Self-citation
A selective sweep in the Spike gene has driven SARS-CoV-2 human adaptation
Kang, L., He, G., Sharp, A. K., Wang, X., Brown, A. M., Michalak, P., & Weger‐Lucarelli, J. (2021) · Cell · doi:10.1016/j.cell.2021.07.007 · Cited by 99
Enhanced fitness of SARS-CoV-2 variant of concern Alpha but not Beta
Ulrich, L., Halwe, N. J., Taddeo, A., Ebert, N., Schön, J., Devisme, C., Trüeb, B. S., Hoffmann, B., Wider, M., Fan, X., et al. (2021) · Nature · doi:10.1038/s41586-021-04342-0 · Cited by 98
COVID-19: Challenges of Viral Variants
Jacobs, J. L., Haidar, G., & Mellors, J. W. (2022) · Annual Review of Medicine · doi:10.1146/annurev-med-042921-020956 · Cited by 105
Characterization and structural basis of a lethal mouse-adapted SARS-CoV-2
Sun, S., Gu, H., Cao, L., Chen, Q., Ye, Q., Yang, G., Li, R.-T., Fan, H., Deng, Y.-Q., Song, X., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25903-x · Cited by 104
Smartphone-Based SARS-CoV-2 and Variants Detection System using Colorimetric DNAzyme Reaction Triggered by Loop-Mediated Isothermal Amplification (LAMP) with Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)
Song, J., Cha, B., Moon, J., Jang, H., Kim, S., Jang, J., Yong, D., Kwon, H., Lee, I., Lim, E., et al. (2022) · ACS Nano · doi:10.1021/acsnano.2c04840 · Cited by 104
Natural and Experimental SARS-CoV-2 Infection in Domestic and Wild Animals
Meekins, D. A., Gaudreault, N. N., & Richt, J. A. (2021) · Viruses · doi:10.3390/v13101993 · Cited by 105
Simeprevir Potently Suppresses SARS-CoV‑2 Replication and Synergizes with Remdesivir
Lo, H. S., Hui, K. P. Y., Lai, H. M., He, X., Khan, K. S., Kaur, S., Huang, J., Li, Z., Chan, A., Cheung, H. H.-Y., et al. (2021) · ACS Central Science · doi:10.1021/acscentsci.0c01186 · Cited by 104
Intra-host evolution during SARS-CoV-2 prolonged infection
Voloch, C. M., Francisco, R. D. S., de Almeida, L. G. P., Brustolini, O. J. B., Cardoso, C. C., Gerber, A. L., Guimarães, A. P. D. C., Leitão, I. D. C., Mariani, D., Ota, V. A., et al. (2021) · Virus Evolution · doi:10.1093/ve/veab078 · Cited by 99
The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Corcern
Akkız, H. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.849217 · Cited by 102
Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice
(2021) · doi:10.1016/j.vaccine.2021.11.001 · Cited by 101
Designing Post COVID-19 Buildings: Approaches for Achieving Healthy Buildings
Navaratnam, S., Nguyen, K. T. Q., Selvaranjan, K., Zhang, G., Mendis, P. A., & Aye, L. (2022) · Buildings · doi:10.3390/buildings12010074 · Cited by 109
Emergence of immune escape at dominant SARS-CoV-2 killer T cell epitope
Dolton, G. M., Rius, C., Hasan, M. S., Wall, A., Szomolay, B., Behiry, E. M., Whalley, T., Southgate, J., Fuller, A., Morin, T., et al. (2022) · Cell · doi:10.1016/j.cell.2022.07.002 · Cited by 100
The SARS-CoV-2 Y453F mink variant displays a pronounced increase in ACE-2 affinity but does not challenge antibody neutralization
Bayarri‐Olmos, R., Rosbjerg, A., Johnsen, L. B., Helgstrand, C., Bak-Thomsen, T. H., Garred, P., & Skjoedt, M. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100536 · Cited by 99
SARS‐CoV‐2 B.1.617 Indian variants: Are electrostatic potential changes responsible for a higher transmission rate?
Pascarella, S., Ciccozzi, M., Zella, D., Bianchi, M., Benedetti, F., Benvenuto, D., Broccolo, F., Cauda, R., Caruso, A., Angeletti, S., et al. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27210 · Cited by 100
Could new COVID variants undermine vaccines? Labs scramble to find out
Callaway, E. (2021) · Nature · doi:10.1038/d41586-021-00031-0 · Cited by 102
Recombinant SARS-CoV-2 genomes circulated at low levels over the first year of the pandemic
VanInsberghe, D., Neish, A. S., Lowen, A. C., & Koelle, K. (2021) · Virus Evolution · doi:10.1093/ve/veab059 · Cited by 99
Global landscape of SARS-CoV-2 mutations and conserved regions
Abbasian, M. H., Mahmanzar, M., Rahimian, K., Mahdavi, B., Tokhanbigli, S., Moradi, B., Sisakht, M. M., & Deng, Y. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-03996-w · Cited by 101
Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2
Xia, H., Zou, J., Kurhade, C., Cai, H., Yang, Q., Cutler, M. W., Cooper, D., Muik, A., Jansen, K. U., Xie, X., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.02.015 · Cited by 102
Self-citation
Neutralization and Stability of SARS-CoV-2 Omicron VariantPreprint
Zeng, C., Evans, J. P., Qu, P., Faraone, J. N., Zheng, Y.-M., Carlin, C., Bednash, J. S., Zhou, T., Lozanski, G., Mallampalli, R. K., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.16.472934 · Cited by 87
Risk of rapid evolutionary escape from biomedical interventions targeting SARS-CoV-2 spike protein
Egeren, D. V., Novokhodko, A., Stoddard, M., Tran, U., Zetter, B. R., Rogers, M. S., Pentelute, B. L., Carlson, J. M., Hixon, M. S., Joseph‐McCarthy, D., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0250780 · Cited by 91
Structure, receptor recognition, and antigenicity of the human coronavirus CCoV-HuPn-2018 spike glycoprotein
Tortorici, M. A., Walls, A. C., Joshi, A., Park, Y., Eguia, R. T., Miranda, M. C., Kepl, E., Dosey, A. M., Stevens‐Ayers, T., Boeckh, M. J., et al. (2022) · Cell · doi:10.1016/j.cell.2022.05.019 · Cited by 89
Dynamically evolving novel overlapping gene as a factor in the SARS-CoV-2 pandemic
Nelson, C. W., Ardern, Z., Goldberg, T. L., Meng, C., Kuo, C.-H., Ludwig, C., Kolokotronis, S.-O., & Wei, X. (2020) · eLife · doi:10.7554/elife.59633 · Cited by 87
Molecular evolutionary characteristics of SARS‐CoV‐2 emerging in the United States
Wang, S., Xu, X., Wei, C., Li, S., Zhao, J., Zheng, Y., Liu, X., Zeng, X., Yuan, W., & Peng, S. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27331 · Cited by 87
The emergence and ongoing convergent evolution of the N501Y lineages coincides with a major global shift in the SARS-CoV-2 selective landscape
Martin, D. P., Weaver, S., Tegally, H., San, E. J., Shank, S. D., Wilkinson, E., Lucaci, A. G., Giandhari, J., Naidoo, S., Pillay, Y., et al. (2021) · doi:10.1101/2021.02.23.21252268 · Cited by 291
Self-citation
Functional importance of the D614G mutation in the SARS-CoV-2 spike protein
Jackson, C. B., Zhang, L., Farzan, M., & Choe, H. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.11.026 · Cited by 93
SARS-CoV-2 mutations acquired in mink reduce antibody-mediated neutralization
Hoffmann, M., Zhang, L., Krüger, N., Graichen, L., Kleine‐Weber, H., Hofmann-Winkler, H., Kempf, A. M., Nessler, S., Riggert, J., Winkler, M. S., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109017 · Cited by 94
Emerging viruses: Cross-species transmission of coronaviruses, filoviruses, henipaviruses, and rotaviruses from bats
Tian, J., Sun, J., Li, D., Wang, N., Wang, L., Zhang, C., Meng, X., Ji, X., Suchard, M. A., Zhang, X., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110969 · Cited by 98
Self-citation
Identification of a conserved S2 epitope present on spike proteins from all highly pathogenic coronaviruses
Silva, R. P., Huang, Y., Nguyen, A. W., Hsieh, C., Olaluwoye, O. S., Kaoud, T. S., Wilen, R. E., Qerqez, A. N., Park, J., Khalil, A. M., et al. (2023) · eLife · doi:10.7554/elife.83710 · Cited by 86
Self-citation
COVID-19 virtual patient cohort suggests immune mechanisms driving disease outcomes
Jenner, A. L., Aogo, R. A., Alfonso, S., Crowe, V., Deng, X., Smith, A. P., Morel, P. A., Davis, C. L., Smith, A. M., & Craig, M. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009753 · Cited by 91
Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice
Ying, B., Scheaffer, S. M., Whitener, B. M., Liang, C.-Y., Dmytrenko, O., Mackin, S., Wu, K., Lee, D. W., Avena, L. E., Chong, Z., et al. (2022) · Cell · doi:10.1016/j.cell.2022.03.037 · Cited by 109
A live-attenuated SARS-CoV-2 vaccine candidate with accessory protein deletions
Liu, Y., Zhang, X., Liu, J., Xia, H., Zou, J., Muruato, A. E., Periasamy, S., Kurhade, C., Plante, J. A., Bopp, N. E., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31930-z · Cited by 92
Self-citation
Global SARS-CoV-2 genomic surveillance: What we have learned (so far)
Tosta, S. F. D. O., Moreno, K. M. F., Schuab, G., Fonseca, V., Cardozo, F., Kashima, S. H., Elias, M. C., Sampaio, S. C., Ciccozzi, M., Alcantara, L. C. J., et al. (2023) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2023.105405 · Cited by 92
Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains
Ying, B., Whitener, B., VanBlargan, L. A., Hassan, A. O., Shrihari, S., Liang, C.-Y., Karl, C. E., Mackin, S., Chen, R. E., Kafai, N. M., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abm3302 · Cited by 85
SARS-CoV-2 Variants Increase Kinetic Stability of Open Spike Conformations as an Evolutionary Strategy
Yang, Z., Han, Y., Ding, S., Shi, W., Zhou, T., Finzi, A., Kwong, P. D., Mothes, W., & Lu, M. (2022) · mBio · doi:10.1128/mbio.03227-21 · Cited by 78
Contribution of single mutations to selected SARS-CoV-2 emerging variants spike antigenicity
Gong, S. Y., Chatterjee, D., Richard, J., Prévost, J., Tauzin, A., Gasser, R., Bo, Y., Vézina, D., Goyette, G., Gendron‐Lepage, G., et al. (2021) · Virology · doi:10.1016/j.virol.2021.09.001 · Cited by 81
Structural Evaluation of the Spike Glycoprotein Variants on SARS-CoV-2 Transmission and Immune Evasion
Salleh, M. Z., Derrick, J. P., & Deris, Z. Z. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147425 · Cited by 82
SARS-CoV-2 Causes Lung Infection without Severe Disease in Human ACE2 Knock-In Mice
Winkler, E. S., Chen, R. E., Alam, F., Yildiz, S., Case, J. B., Uccellini, M. B., Holtzman, M. J., García‐Sastre, A., Schotsaert, M., & Diamond, M. (2021) · Journal of Virology · doi:10.1128/jvi.01511-21 · Cited by 78
Emerging SARS-CoV-2 Variants: Genetic Variability and Clinical Implications
Dubey, A., Choudhary, S., Kumar, P., & Tomar, S. (2021) · Current Microbiology · doi:10.1007/s00284-021-02724-1 · Cited by 79
Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine
Kurhade, C., Zou, J., Xia, H., Cai, H., Yang, Q., Cutler, M. W., Cooper, D., Muik, A., Jansen, K. U., Xie, X., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30681-1 · Cited by 79
Self-citation
A trans-complementation system for SARS-CoV-2 recapitulates authentic viral replication without virulence
Zhang, X., Liu, Y., Liu, J., Bailey, A. L., Plante, K. S., Plante, J. A., Zou, J., Xia, H., Bopp, N. E., Aguilar, P. V., et al. (2021) · Cell · doi:10.1016/j.cell.2021.02.044 · Cited by 79
Self-citation
PD-1 blockade counteracts post–COVID-19 immune abnormalities and stimulates the anti–SARS-CoV-2 immune response
Loretelli, C., Abdelsalam, A., D’Addio, F., Nasr, M. B., Assi, E., Usuelli, V., Maestroni, A., Seelam, A. J., Ippolito, E., Maggio, S. D., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.146701 · Cited by 81
SARS-CoV-2 evolution on a dynamic immune landscape
Raharinirina, N. A., Gubela, N., Börnigen, D., Smith, M. R., Oh, D., Budt, M., Mache, C., Schillings, C., Fuchs, S., Dürrwald, R., et al. (2025) · Nature · doi:10.1038/s41586-024-08477-8 · Cited by 88
Monitoring of SARS‐CoV‐2 infection in mustelids
Boklund, A., Gortázar, C., Pasquali, P., Roberts, H., Nielsen, S., Ståhl, K., Stegeman, A., Baldinelli, F., Broglia, A., der Stede, Y. V., et al. (2021) · EFSA journal. European Food Safety Authority · doi:10.2903/j.efsa.2021.6459 · Cited by 82
Two-step fitness selection for intra-host variations in SARS-CoV-2
Li, J., Du, P., Yang, L., Zhang, J., Song, C., Chen, D., Song, Y., Ding, N., Hua, M., Han, K., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110205 · Cited by 80
Self-citation
Increased small particle aerosol transmission of B.1.1.7 compared with SARS-CoV-2 lineage A in vivo
Port, J. R., Yinda, C. K., Avanzato, V. A., Schulz, J. E., Holbrook, M. G., van Doremalen, N., Shaia, C., Fischer, R. J., & Munster, V. J. (2022) · Nature Microbiology · doi:10.1038/s41564-021-01047-y · Cited by 77
Structural dynamics in the evolution of SARS-CoV-2 spike glycoprotein
Calvaresi, V., Wrobel, A. G., Toporowska, J., Hammerschmid, D., Doores, K. J., Bradshaw, R. T., Parsons, R. B., Benton, D. J., Roustan, C., Reading, E., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36745-0 · Cited by 81
Mutational signatures and heterogeneous host response revealed via large-scale characterization of SARS-CoV-2 genomic diversity
Graudenzi, A., Maspero, D., Angaroni, F., Piazza, R., & Ramazzotti, D. (2021) · iScience · doi:10.1016/j.isci.2021.102116 · Cited by 76
One year of SARS-CoV-2 evolution
Wu, A., Wang, L., Zhou, H., Ji, C., Xia, S., Cao, Y., Meng, J., Ding, X. L., Gold, S., Jiang, T., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.02.017 · Cited by 73
SARS-CoV-2 Infection: New Molecular, Phylogenetic, and Pathogenetic Insights. Efficacy of Current Vaccines and the Potential Risk of Variants
Rotondo, J. C., Martini, F., Maritati, M., Mazziotta, C., Mauro, G. D., Lanzillotti, C., Barp, N., Gallerani, A., Tognon, M. G., & Contini, C. (2021) · Viruses · doi:10.3390/v13091687 · Cited by 81
Monitoring Natural SARS-CoV-2 Infection in Lions (Panthera leo) at the Barcelona Zoo: Viral Dynamics and Host Responses
Fernández-Bellón, H., Rodon, J., Fernández‐Bastit, L., Almagro, V., Padilla-Solé, P., Lorca-Oró, C., Valle, R. M., Roca, N., Grazioli, S., Trogu, T., et al. (2021) · Viruses · doi:10.3390/v13091683 · Cited by 75
B.1.617.2 enters and fuses lung cells with increased efficiency and evades antibodies induced by infection and vaccination
Arora, P., Sidarovich, A., Krüger, N., Kempf, A. M., Nehlmeier, I., Graichen, L., Moldenhauer, A.-S., Winkler, M. S., Schulz, S. R., Jäck, H., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109825 · Cited by 87
Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein
Suryadevara, N., Shrihari, S., Gilchuk, P., VanBlargan, L. A., Binshtein, E., Zost, S. J., Nargi, R. S., Sutton, R. E., Winkler, E. S., Chen, E. C., et al. (2021) · doi:10.1101/2021.01.19.427324 · Cited by 361
Evolution of SARS-CoV-2: Review of Mutations, Role of the Host Immune System
Banoun, H. (2021) · The Nephron journals/Nephron journals · doi:10.1159/000515417 · Cited by 77
Mutation Y453F in the spike protein of SARS-CoV-2 enhances interaction with the mink ACE2 receptor for host adaption
Ren, W., Lan, J., Ju, X., Gong, M., Long, Q., Zhu, Z., Yu, Y., Wu, J., Zhong, J., Zhang, R., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1010053 · Cited by 74

Authors: Plante, J. A., Liu, Y., Liu, J., Xia, H., Johnson, B. A., Lokugamage, K. G., Zhang, X., Muruato, A. E., Zou, J., Fontes-Garfias, C. R., Mirchandani, D., Scharton, D., Bilello, J. P., Ku, Z., An, Z., Kalveram, B., Freiberg, A. N., Menachery, V. D., Xie, X., Plante, K. S., Weaver, S. C., & Shi, P.-Y.
Affiliations: The University of Texas Medical Branch at Galveston (US)
Gilead Sciences (United States) (US)
Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases (US)
Corresponding author: Xie, Xuping
Plante, Kenneth S.
Weaver, Scott C.
Shi, Pei-Yong
ORCID: Plante, Jessica A.
Liu, Jianying
Xia, Hongjie
Johnson, Bryan A.
Zhang, Xianwen
Zou, Jing
Fontes-Garfias, Camila R.
Scharton, Dionna
Bilello, John P.
Ku, Zhiqiang
An, Zhiqiang
Freiberg, Alexander N.
Menachery, Vineet D.
Xie, Xuping
Plante, Kenneth S.
Weaver, Scott C.
Shi, Pei-Yong
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2020-10-26
Volume: 592
Issue: 7852
Pages: 116-121
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/s41586-020-2895-3
PMC: PMC8158177
OpenAlex: W3093768302
Cited by: 1,558
References: 37
Citations by year: 2026: 37 · 2025: 73 · 2024: 120 · 2023: 174 · 2022: 427 · 2021: 670 · 2020: 55
FWCI: 43.60
Type: journal article
Language: en
Update notices: correction (2021-06-15)
Open access: bronze
doi.org
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature (publishedVersion)
bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
PubMed Central (submittedVersion, cc-by-nc-nd)
RePEc: Research Papers in Economics (submittedVersion)
Funders: Amon G. Carter Foundation
John S. Dunn Foundation (AI145617)
University of Texas System
Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation (AI134907)
National Institutes of Health (AG049042, TL1TR001440, AI145617, AI142759, UL1TR001439)
National Institute on Aging (AI142759, AG049042, R00AG049092)
National Institute of Allergy and Infectious Diseases (R43AI145617, AI142759, R24AI120942, R01AI134907, R21AI145400, U01AI151801, U19AI142759, R01AI153602, AI153602, AG049042, AI134907, AI145617, UC7AI094660)
National Center for Advancing Translational Sciences
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Keywords: SARS-CoV-2, viral fitness, viral replication, upper respiratory tract infection, virus transmission, neutralizing antibodies, vaccine efficacy, hamster model, lung epithelial cells, therapeutic antibodies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Spike mutation D614G alters SARS-CoV-2 fitness

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks